THERMOPLASTIC SILOXANE-URETHANE COPOLYMER DEVELOPMENT

该项目将检验热塑性塑料生物稳定性的假设 聚氨酯(TPU)可以通过全部或部分取代 远螺旋聚二甲基硅氧烷(PSX)聚醚软段 合成过程中的低聚物。这种方法是基于已报道的 通过提高溶剂型浇铸聚氨酯的体内稳定性 反应性PSX与氨酯瓶聚合物的混合或接枝 以及已知的PSX的体内稳定性。 在第一阶段，几种不同药物的皮下体内稳定性 将测定聚氨基甲酸酯。来自PSX的芳香族TPU， 聚四亚甲基醚、聚环氧乙烷和几种PSX/聚醚 三元共聚聚氨酯薄膜在种植后将通过 能够检测相对分子质量的本体和表面分析方法 与之相关的表面化学和形态的还原和变化 降解的过程。 积极的第一阶段结果将在第二阶段完成 生物医用PSX-TPU家族的开发和商业化。 这些材料将适用于溶剂铸造、挤压和 注塑成型。它们将结合生物降解性和 PSX具有理想的表面性能，加工容易且范围广 常规热塑性聚氨酯中可用的一系列散装特性。

This project would test the hypothesis that biostability of thermoplastic polyurethanes (TPU) can be improved by replacing all or part of the polyether soft segment with telechelic polydimethylsiloxane (PSX) oligomer during synthesis. This approach is based on the reported improvement in-vivo stability of solvent-cast polyurethanes through the admixture or grafting of reactive PSX into/onto urethane vased polymers and the known in-vivo stability of PSX. In Phase I the subcutaneous in-vivo stability of several different polyurethane will be determined. Aromatic TPUs from PSX, polytetramethyleneoxide and polyethyleneoxide and several PSX/polyether terpolymer polyurethane films will be characterized after explantation by bulk and surface analytical methods capable of detecting molecular weight reduction and changes in surface chemistry and morphology associated with the degradation process. Positive phase I results will be utilized in Phase II to complete the development and commercialization of a family of biomedical PSX-TPUs. These materials will be suitable for solvent casting, extrusion and injection molding. They will combine the biodegradation resistance and desirable surface properties of PSX, with the processing ease and wide range of bulk properties available in conventional TPUs.